211 related articles for article (PubMed ID: 33746213)
1. Evolving role of
Satapathy S; Sood A; Das CK; Mittal BR
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):880-890. PubMed ID: 33746213
[TBL] [Abstract][Full Text] [Related]
2. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
[TBL] [Abstract][Full Text] [Related]
3.
Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C
Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559
[TBL] [Abstract][Full Text] [Related]
4. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
[TBL] [Abstract][Full Text] [Related]
5. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
6. Effects of
Lee DY; Kim YI
J Nucl Med; 2022 Jun; 63(6):840-846. PubMed ID: 34503960
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
van der Doelen MJ; Mehra N; van Oort IM; Looijen-Salamon MG; Janssen MJR; Custers JAE; Slootbeek PHJ; Kroeze LI; Bruchertseifer F; Morgenstern A; Haberkorn U; Kratochwil C; Nagarajah J; Gerritsen WR
Urol Oncol; 2021 Oct; 39(10):729.e7-729.e16. PubMed ID: 33353867
[TBL] [Abstract][Full Text] [Related]
8. [
Satapathy S; Sahoo RK; Bal C
J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.
Parida GK; Panda RA; Bishnoi K; Agrawal K
Med Princ Pract; 2023; 32(3):178-191. PubMed ID: 37247612
[TBL] [Abstract][Full Text] [Related]
10.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
12. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Satapathy S; Mittal BR; Sood A
Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
[TBL] [Abstract][Full Text] [Related]
13. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
14. Hematologic toxicity profile and efficacy of [
Lawal IO; Morgenstern A; Vorster M; Knoesen O; Mahapane J; Hlongwa KN; Maserumule LC; Ndlovu H; Reed JD; Popoola GO; Mokoala KMG; Mdlophane A; Bruchertseifer F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3581-3592. PubMed ID: 35384462
[TBL] [Abstract][Full Text] [Related]
15. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
16. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
19. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
